Product Watch, October 2008

Oct 01, 2008

Product watch, October 2008

Please click on any of the headlines below to see the full story.

UK reimburses Lucentis… at last!
The UK's medical reimbursement governing body, the National Institute for Health and Clinical Excellence (NICE), is to reimburse Lucentis (ranibizumab; Novartis) jointly with Novartis under a dose-capping scheme, reversing NICE's earlier, much derided, decision not to reimburse the drug. 

Cardiovascular drug might treat diabetic retinopathy
A drug that has traditionally been used to treat cardiovascular conditions has shown promise in the treatment and prevention of diabetic retinopathy. The claim was based on data from a large-scale programme assessing the effect of an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye disease. Findings from the study will be published in The Lancet

 

For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.

x